Published in Nature on October 03, 1991
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84
The Trojan exosome hypothesis. Proc Natl Acad Sci U S A (2003) 3.45
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol (1997) 1.72
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68
Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol (1995) 1.63
Strategies for an HIV vaccine. J Clin Invest (2002) 1.42
Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med (2007) 1.41
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol (1994) 1.32
Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J Virol (2003) 1.32
Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol (1992) 1.32
Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol (1993) 1.27
AIDS vaccine developments. Nature (1992) 1.15
Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol (1995) 1.14
Passive antibody protection of cats against feline immunodeficiency virus infection. J Virol (1993) 1.14
Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol (2006) 1.13
Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol (1995) 1.11
AIDS vaccine developments. Nature (1992) 1.11
Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol (1997) 1.11
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol (1994) 1.10
AIDS vaccine developments. Nature (1992) 1.08
Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J Virol (1996) 1.08
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol (1994) 0.97
Monkey business over AIDS vaccine. BMJ (1991) 0.95
Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV. Vet Immunol Immunopathol (2009) 0.93
Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology (2011) 0.92
Sulfation of the human immunodeficiency virus envelope glycoprotein. J Virol (1992) 0.92
Prevalence of serologic reactivity against four strains of mouse mammary tumour virus among US women with breast cancer. Br J Cancer (2006) 0.91
CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses (2010) 0.91
Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology (1994) 0.88
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest (1993) 0.87
No acquisition: a new ambition for HIV vaccine development? Curr Opin Virol (2011) 0.87
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies. J Virol (2007) 0.85
Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J Virol (1992) 0.84
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. Clin Diagn Lab Immunol (1998) 0.84
Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus. J Virol (1995) 0.84
HLA-C and HIV-1: friends or foes? Retrovirology (2012) 0.83
Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy. F1000 Med Rep (2011) 0.82
AIDS response. Nature (1991) 0.81
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. J Virol (1999) 0.81
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. J Virol (2011) 0.80
Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages. J Virol (1992) 0.80
Efficacy of AIDS vaccine strategies in nonhuman primates. Med Microbiol Immunol (2005) 0.79
A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation. Clin Exp Immunol (1992) 0.79
Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells. Immunology (2009) 0.78
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel) (2016) 0.77
Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems. Immunology (2007) 0.76
Prior mucosal exposure to heterologous cells alters the pathogenesis of cell-associated mucosal feline immunodeficiency virus challenge. Retrovirology (2010) 0.75
Brief Report: Enhanced Allogeneic Cellular Responses to Mismatched HLA-B Antigens Results in More Efficient Killing of HIV Infected Cells. J Acquir Immune Defic Syndr (2016) 0.75
AIDS vaccine: new ideas from old approaches. J R Soc Med (2003) 0.75
Where are we now with vaccines against AIDS? BMJ (1993) 0.75
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS. PLoS One (2014) 0.75
Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex. J Virol (1993) 0.75
Greater ethnic diversity correlates with lower HIV prevalence in Africa: justification for an alloimmunity vaccine. HIV AIDS (Auckl) (2013) 0.75
Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor. J Biomed Biotechnol (2008) 0.75
New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet (1971) 5.41
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet (1995) 3.47
Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 3.27
Influenza, respiratory syncytial virus, and pneumonia in Glasgow, 1962-5. Br Med J (1967) 2.76
Respiratory syncytial virus. Brief review. Arch Virol (1985) 2.31
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol (1986) 2.18
Respiratory syncytial virus infection in mice. Infect Immun (1984) 2.14
Some improved techniques for the study of rhinoviruses using HeLa cells. Arch Gesamte Virusforsch (1968) 2.13
Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology (1987) 2.02
Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol (1987) 1.98
The detection of respiratory syncytial virus in nasopharyngeal aspirates: assessment, formulation, and evaluation of monoclonal antibodies as a diagnostic reagent. J Med Virol (1986) 1.93
Rhinoviruses. Annu Rev Microbiol (1972) 1.90
An investigation of media for the long term storage of three respiratory viruses. Arch Gesamte Virusforsch (1974) 1.78
Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol (1992) 1.73
Viral contamination of bovine foetal serum and cell cultures. Nature (1977) 1.65
Immune electron microscopy of rhinoviruses. J Virol (1972) 1.64
Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol (1997) 1.62
Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses (1992) 1.60
Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus. J Gen Virol (1985) 1.52
A survey of virus infections of the respiratory tract of cattle and their association with disease. J Hyg (Lond) (1980) 1.49
Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS (1991) 1.39
Factors affecting the growth of Rhinovirus 2 in suspension cultures of L132 cells. J Gen Virol (1970) 1.38
Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol (1987) 1.38
A comparison of three vaccines against respiratory syncytial virus in calves. J Hyg (Lond) (1984) 1.27
Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J Virol (1994) 1.25
Identification of rhinovirus stran D.C. Nature (1968) 1.24
Molecular weight of rhinovirus ribonucleic acid. J Gen Virol (1970) 1.17
Characterization of bovine respiratory syncytial virus proteins and mRNAs and generation of cDNA clones to the viral mRNAs. J Virol (1989) 1.17
Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol (1992) 1.14
Studies of respiratory viruses in personnel at an Antarctic base. J Hyg (Lond) (1971) 1.14
A comparative virological study of children in hospital with respiratory and diarrhoeal illnesses. J Hyg (Lond) (1967) 1.12
Antigenic variation among strains of rhinovirus type 51. Nature (1969) 1.12
A reverse passive haemagglutination test for the detection of respiratory syncytial virus in nasal secretions from infants. J Med Virol (1981) 1.07
Rhinovirus infections of children in hospital; isolation of three possibly new rhinovirus serotypes. Am J Epidemiol (1969) 1.07
Studies of experimental rhinovirus type 2 infections in polar isolation and in England. J Hyg (Lond) (1976) 1.07
Experimentally produced calf pneumonia. Res Vet Sci (1976) 1.05
A search for new microorganisms in calf pneumonia by the inoculation of gnotobiotic calves. Res Vet Sci (1982) 1.04
Histopathological changes in simian immunodeficiency virus infection. J Pathol (1990) 0.99
Cytotoxicity of alveolar macrophages for virus-infected cells. Nature (1975) 0.99
Rhinoviraemia. Br Med J (1970) 0.99
Evaluation of respiratory disease in calves: comparison of disease response to different viruses. Res Vet Sci (1977) 0.98
Protection against respiratory disease in calves induced by vaccines containing respiratory syncytial virus, parainfluenza type 3 virus, Mycoplasma bovis and M dispar. Vet Rec (1987) 0.97
Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage. J Gen Virol (1992) 0.96
The effect of pneumonia induced in mice with Mycoplasma pulmonis on resistance to subsequent bacterial infection and the effect of a respiratory infection with Sendai virus on the resistance of mice to Mycoplasma pulmonis. J Gen Microbiol (1978) 0.96
The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates. AIDS Res Hum Retroviruses (1997) 0.95
Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity. J Immunol (1991) 0.94
Induction of pneumonia in gnotobiotic calves following inoculation of Mycoplasma dispar and ureaplasmas (T-mycoplasmas). Res Vet Sci (1976) 0.93
Virological studies in chronic bronchitis. Br Med J (1966) 0.92
Interactions between calf alveolar macrophages and parainfluenza-3 virus. Infect Immun (1977) 0.89
In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. J Gen Virol (2001) 0.89
An outbreak of common colds at an Antarctic base after seventeen weeks of complete isolation. J Hyg (Lond) (1973) 0.89
The maintenance of liver cells in vitro for virological and other studies. Br J Exp Pathol (1974) 0.88
The possible role of respiratory syncytial virus and Pasteurella spp in calf respiratory disease. Vet Rec (1980) 0.88
Monoclonal antibodies protect against respiratory syncytial virus. Lancet (1983) 0.88
Haemagglutination by rhinoviruses. Lancet (1972) 0.86
Selection of variants of rhinoviruses. Arch Gesamte Virusforsch (1968) 0.86
Human embryo kidney fibroblasts for the isolation and growth of rhinoviruses. Br J Exp Pathol (1967) 0.86
Diagnosis of respiratory syncytial virus infection in the bovine respiratory tract by immunofluorescence. Vet Rec (1981) 0.86
The characterization and uses of monoclonal antibodies to respiratory syncytial virus. Dev Biol Stand (1984) 0.86
Experimental infection of calves with two strains of bovine virus diarrhoea virus: virus recovery and clinical reactions. Res Vet Sci (1980) 0.86
The use of the polymerase chain reaction for the detection of Simian immunodeficiency virus in experimentally infected macaques. J Virol Methods (1990) 0.85
Rhinovirus infections in Glasgow in 1962-66. Bull World Health Organ (1969) 0.85
The effect of temperature on the synthesis of rhinovirus type 2 RNA. J Gen Virol (1977) 0.85
Production and characterization of bovine monoclonal antibodies to respiratory syncytial virus. J Gen Virol (1988) 0.84
Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch Virol (1991) 0.84
Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins. J Med Primatol (1992) 0.84
Mycoplasma bovis infection in gnotobiotic calves and combined infection with respiratory syncytial virus. Vet Pathol (1986) 0.84
Progressive dendritic pathology in cynomolgus macaques infected with simian immunodeficiency virus. Neuropathol Appl Neurobiol (1999) 0.83
Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. J Gen Virol (1991) 0.82
Absence of heterologous antibody responses in human volunteers after rhinovirus vaccination. (Brief report). Arch Gesamte Virusforsch (1969) 0.82
Effect of vaccination on cell populations in lung washes from calves after infection with respiratory syncytial virus. Res Vet Sci (1989) 0.82
Virus contamination of bovine testis cell cultures. Res Vet Sci (1981) 0.82
Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res Hum Retroviruses (1994) 0.82
Infection of gnotobiotic calves with a bovine and human isolate of respiratory syncytial virus. Modification of the response by dexamethasone. Arch Virol (1984) 0.81
Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells. J Med Primatol (1997) 0.80
The response of bovine lymphocytes from lymph and blood to phytohaemagglutinin. Vet Immunol Immunopathol (1979) 0.80
Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages. J Virol (1992) 0.80
The growth of respiratory syncytial virus in organ cultures of bovine foetal trachea. Arch Virol (1976) 0.80
Comparison of three methods for sampling the bovine upper respiratory tract for viruses. Res Vet Sci (1975) 0.79
Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo. J Med Primatol (2007) 0.78
Experimental infection of calves with two strains of bovine virus diarrhoea virus: certain immunological reactions. Vet Immunol Immunopathol (1980) 0.78
Changes in neuron size in cynomolgus macaques infected with various immunodeficiency viruses and poliovirus. Neuropathol Appl Neurobiol (1998) 0.78
Monoclonal antibodies recognize at least five epitopes on the SIV Nef protein and identify an in vitro-induced mutation. AIDS Res Hum Retroviruses (1999) 0.77
Lymphocyte transformation response of calves to respiratory syncytial virus. J Med Virol (1987) 0.77
Where are we now with vaccines against AIDS? BMJ (1993) 0.75
Clinical and virological investigations of acute respiratory disease in children outside hospital. J R Coll Gen Pract (1970) 0.75
An inactivated parainfluenza virus type 3 vaccine: the influence of vaccination regime on the response of calves and their subsequent resistance to challenge. Res Vet Sci (1978) 0.75
Effects of recombinant human alpha A interferon in gnotobiotic calves challenged with respiratory syncytial virus. Res Vet Sci (1991) 0.75
The quest for vaccines against AIDS: progress and challenges. An overview. Vaccine (1991) 0.75
Transmission studies with simian immunodeficiency virus of macaques; persistent infection of baboons. Intervirology (1992) 0.75
Oral administration of rhinoviruses grown at different temperatures in human diploid cells. (Briefeport). Arch Gesamte Virusforsch (1969) 0.75
The common cold. Practitioner (1970) 0.75
Construction of infectious SIV/HIV-2 chimeras. AIDS (2000) 0.75
Cytokine profiling of simian immunodeficiency virus infection of cynomologus macaques. Pathogenic SIVmac251 pJ5C versus non-pathogenic attenuated SIVmac251 pC8C reveals divergence. Biochem Soc Trans (1997) 0.75
Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines. AIDS Res Hum Retroviruses (1992) 0.75
The polypeptides of three rhinoviruses. J Gen Virol (1973) 0.75
The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus. J Gen Virol (1999) 0.75
The importance of picornavirus infections in respiratory disease of man and other mammals. Dev Biol Stand (1975) 0.75
Comparison of peripheral blood phenotype in pathogenic and attenuated SIV infection. Biochem Soc Trans (1997) 0.75
Virus infections in bovine respiratory disease. Vet Rec (1984) 0.75